Replies to post #29026 on PharmaCyte Biotech Inc (PMCB)

[walterm32]

I agree with everything you've said. What I meant by revenue generating news is exactly your 4th point:
4. FDA Fast-track will skyrocket the price and will hold barring bad news from the field.
If your #4 happens that means revenue is eventually coming.
The very reason I haven't been long on NVLX is because I knew it was a long way from getting to the fast track point. Meaning dilution was the only way for NVLX to raise capital. I've been in and out of this stock more than a few times since Feb and have done well playing the swings. I'll be back in again but not until it drops below $.016.